INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $398 | +76.9% | 7,637 | +115.9% | 0.00% | 0.0% |
| Q2 2023 | $225 | -3.4% | 3,537 | -17.5% | 0.00% | 0.0% |
| Q1 2023 | $233 | +2.2% | 4,289 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $228 | -99.9% | 4,289 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $199,000 | -18.8% | 4,289 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $245,000 | -5.4% | 4,289 | +7.7% | 0.00% | 0.0% |
| Q1 2022 | $259,000 | +43.1% | 3,984 | +14.4% | 0.00% | – |
| Q4 2021 | $181,000 | +18.3% | 3,481 | -14.6% | 0.00% | – |
| Q3 2021 | $153,000 | -7.8% | 4,074 | 0.0% | 0.00% | – |
| Q2 2021 | $166,000 | -1.8% | 4,074 | -18.9% | 0.00% | – |
| Q1 2021 | $169,000 | +26.1% | 5,025 | +19.4% | 0.00% | – |
| Q4 2020 | $134,000 | +24.1% | 4,208 | 0.0% | 0.00% | – |
| Q3 2020 | $108,000 | +0.9% | 4,208 | 0.0% | 0.00% | – |
| Q2 2020 | $107,000 | +64.6% | 4,208 | 0.0% | 0.00% | – |
| Q1 2020 | $65,000 | -54.5% | 4,208 | 0.0% | 0.00% | – |
| Q4 2019 | $143,000 | +197.9% | 4,208 | +13.2% | 0.00% | – |
| Q2 2019 | $48,000 | +6.7% | 3,718 | -0.7% | 0.00% | – |
| Q1 2019 | $45,000 | +9.8% | 3,745 | 0.0% | 0.00% | – |
| Q4 2018 | $41,000 | -49.4% | 3,745 | 0.0% | 0.00% | – |
| Q3 2018 | $81,000 | +22.7% | 3,745 | 0.0% | 0.00% | – |
| Q2 2018 | $66,000 | -16.5% | 3,745 | 0.0% | 0.00% | – |
| Q1 2018 | $79,000 | +46.3% | 3,745 | 0.0% | 0.00% | – |
| Q4 2017 | $54,000 | -6.9% | 3,745 | 0.0% | 0.00% | – |
| Q3 2017 | $58,000 | +26.1% | 3,745 | 0.0% | 0.00% | – |
| Q2 2017 | $46,000 | -24.6% | 3,745 | 0.0% | 0.00% | – |
| Q1 2017 | $61,000 | +7.0% | 3,745 | 0.0% | 0.00% | – |
| Q4 2016 | $57,000 | -50.0% | 3,745 | -50.0% | 0.00% | – |
| Q3 2016 | $114,000 | -21.4% | 7,490 | +100.0% | 0.00% | – |
| Q2 2016 | $145,000 | +39.4% | 3,745 | 0.0% | 0.00% | – |
| Q1 2016 | $104,000 | -16.8% | 3,745 | +61.6% | 0.00% | – |
| Q4 2015 | $125,000 | +34.4% | 2,318 | 0.0% | 0.00% | – |
| Q3 2015 | $93,000 | +25.7% | 2,318 | 0.0% | 0.00% | – |
| Q2 2015 | $74,000 | – | 2,318 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
| EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
| Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
| Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
| SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
| GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
| BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
| Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
| Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
| Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |